Alpharadin

Related by string. * * Alpharadin radium *

Related by context. All words. (Click for frequent words.) 70 Azedra 69 HuMax EGFr 68 indibulin 68 OncoVEX GM CSF 67 IMA# 67 Proxinium TM 67 CR# vcMMAE 67 ELACYT 67 Tyrima 67 IRX 2 66 Tarvacin 66 AEG# 66 YONDELIS 66 HuMax CD4 66 Carfilzomib 66 phase IIa clinical 66 Vicinium TM 65 BAY #-# 65 Bezielle 65 HQK 65 obatoclax 65 liposomal formulation 65 JAK inhibitor 65 oral prodrug 65 Aplidin 65 phase IIb clinical 65 anticancer compound 64 vascular disrupting agent 64 Sym# 64 Traficet EN 64 Archexin 64 oral ridaforolimus 64 mertansine 64 elacytarabine 64 PRT# 64 XmAb# 64 Perifosine 64 superficial bladder cancer 64 oral antiviral 64 Phase Ib study 64 Exherin TM 64 metaglidasen 64 NP2 Enkephalin 64 Fodosine 64 Cotara 64 Amrubicin 64 Debio 64 IMGN# 63 Onconase 63 satraplatin 63 OPAXIO 63 cilengitide 63 Alocrest 63 ThermoDox ® 63 EndoTAG 63 Reolysin 63 pomalidomide 63 EndoTAG TM -1 63 ganetespib 63 anticancer agent 63 CoFactor 63 carfilzomib 63 SNT MC# 63 Tarceva TM 63 romidepsin 63 ASA# 63 Phase III clinical 63 CYT# 63 CEQ# 63 elotuzumab 63 Afatinib 63 BNC# 63 Nanobody ® 63 ISIS # 63 Nanobody 63 farletuzumab 63 PCK# 63 CBLC# 63 Tarvacin TM 63 Phase Ib clinical 63 VA# [002] 62 luliconazole 62 perifosine 62 CCX# 62 ONCONASE 62 eniluracil 62 Ophena TM 62 targeted radiotherapeutic 62 depsipeptide 62 MGCD# [001] 62 Zerenex 62 thymalfasin 62 ZK EPO 62 docetaxel Taxotere R 62 Irinotecan 62 neratinib 62 OHR/AVR# 62 AP# [003] 62 investigational compound 62 HGS ETR1 62 Amplimexon 62 TG# [003] 62 tanespimycin 62 Xanafide 62 BiTE antibody 62 RDEA# 62 ProLindac 62 Dapagliflozin 62 Panzem 62 ixabepilone 62 axitinib 62 Panzem R NCD 62 Darinaparsin 62 BAL# [002] 62 blinatumomab 62 forodesine 62 PXD# 62 oral deforolimus 62 bevacizumab Avastin 62 orally bioavailable 62 proteasome inhibitor 62 pralatrexate 62 Urocidin 62 AEZS 62 PEG SN# 62 PRTX 62 CRLX# 62 NXL# 62 OncoGel 62 HCV protease inhibitor 62 investigational drug 61 OncoVEX 61 DAVANAT 61 ToGA 61 Allovectin 7 ® 61 oxybutynin gel 61 histone deacetylase HDAC inhibitor 61 glufosfamide 61 Anthim 61 INCB# [002] 61 MAGE A3 ASCI 61 RhuDex ® 61 bavituximab 61 EOquin TM 61 Pertuzumab 61 Atiprimod 61 Abiraterone acetate 61 alvespimycin 61 CBLB# 61 ozarelix 61 Factor Xa inhibitor 61 Hsp# inhibitor 61 Onalta 61 MBP# [001] 61 Phase Ib 61 TG# [001] 61 Aurexis 61 picoplatin 61 BrachySil 61 Nexavar ® 61 afamelanotide 61 Tamibarotene 61 zanolimumab 61 Tesetaxel 61 subcutaneous formulation 61 amrubicin 61 afatinib 61 trabectedin 61 riociguat 61 mitogen activated ERK kinase 61 NVA# 61 HuLuc# 61 radiotherapeutic 61 PEGylated interferon 61 Cetrorelix 61 eltrombopag 61 phase IIb 61 radiation sensitizer 61 CA4P 61 Phase IIIb clinical 61 Cloretazine ® 61 OvaRex ® MAb 61 PSMA ADC 61 Zolinza 61 Phase Ib II 61 Loramyc R 61 torezolid phosphate 61 INCB# [001] 61 Quinamed 61 SCH # 61 NEUMUNE 61 Mipomersen 61 Phase 2a trial 61 Silodosin 61 Pirfenidone 61 Allovectin 7 R 61 pain palliation 61 lapatinib Tykerb 61 dirucotide 61 talactoferrin 61 Phase IIa clinical 61 TRO# 61 ADVEXIN 61 MORAb 61 GLPG# 61 Clavis Pharma 61 EOquin 61 HER2 positive metastatic breast 61 Annamycin 60 corticosteroid dexamethasone 60 mapatumumab 60 Phase III 60 triphendiol 60 KNS # 60 LHRH antagonist 60 photoprotective drug 60 Hycamtin 60 Allovectin 7 60 Ophena 60 REOLYSIN ® 60 Ixempra 60 teriflunomide 60 HGS ETR2 60 Chrysalin 60 Bicifadine 60 DAVANAT R 60 RLY# 60 elesclomol 60 selective androgen receptor modulator 60 clofarabine 60 tolerability profile 60 DP b# 60 Pazopanib 60 Gefitinib 60 MEK inhibitors 60 Naproxcinod 60 Apixaban 60 registrational 60 Phase 1b clinical 60 milatuzumab 60 PEP# [003] 60 rilonacept 60 RAPAFLO 60 MAXY G# 60 methylnaltrexone 60 Telatinib 60 imetelstat 60 oxidative stress inducer 60 StemEx R 60 sunitinib malate 60 Ozarelix 60 sorafenib tablets 60 Zalypsis 60 LUX Lung 60 Marqibo 60 monoclonal antibody conjugated 60 ThermoDox 60 adecatumumab 60 Radilex 60 INT# [002] 60 atrasentan 60 TPI ASM8 60 paclitaxel poliglumex 60 Aclidinium 60 eprotirome 60 Diabetic Macular Edema 60 BCX# 60 Myocet 60 relapsed refractory multiple myeloma 60 Apaziquone 60 ADXS# 60 ASONEP 60 T DM1 60 edoxaban 60 aflibercept 60 AQ4N 60 VEGF Trap 60 Phase 1b trial 60 epothilone 60 lorvotuzumab mertansine 60 OMP #M# 60 vinca alkaloid 60 ZYBRESTAT 60 randomized Phase 60 Solazed 60 Protelos 60 entinostat 60 tamibarotene 60 Tavocept 60 Bortezomib 60 Golimumab 60 GRN# 60 phase IIa 60 enzastaurin 60 BEMA TM Fentanyl 60 refractory prostate cancer 60 BIBW 60 pertuzumab 60 pan HDAC inhibitor 60 anti amnesic 60 darinaparsin ZIO 60 PROSTVAC TM 60 MOZOBIL 60 preclinical efficacy 60 Symadex 60 Stimuvax 60 cediranib 60 Radezolid 60 ThermoDox R 60 Chemophase 60 HCV protease inhibitors 60 vorinostat 60 Pemetrexed 60 hematological cancers 60 SCCHN 60 vascular disrupting agents 60 phase IIb trial 60 Epanova 60 Phase 1b 60 ORMD 60 rindopepimut 60 TRISENOX 60 BioNumerik 60 investigational humanized monoclonal antibody 60 Phase #b/#a 59 tivozanib 59 therapeutic monoclonal antibody 59 huC# DM4 59 MAP# 59 DU #b 59 relapsed ovarian cancer 59 CAPHOSOL 59 orally dosed 59 docetaxel Taxotere ® 59 TACI Ig 59 oncolytic vaccine 59 sulodexide 59 HCD# [002] 59 L BLP# 59 Campath ® 59 LibiGel ® 59 nimotuzumab 59 Phase 2a 59 sorafenib Nexavar 59 IAP inhibitors 59 isavuconazole 59 pivotal Phase III 59 deforolimus 59 XL# [003] 59 protein kinase inhibitor 59 Vorinostat 59 proteasome inhibitors 59 alvimopan 59 DXL# 59 IL# PE#QQR 59 Gliadel Wafer 59 FOLOTYN ® 59 viral kinetic 59 Menerba 59 TriRima 59 #D#C# 59 Bavituximab 59 Litx 59 Taxotere ® 59 Neuradiab 59 elagolix 59 phase Ib 59 Cloretazine R VNP#M 59 Picoplatin 59 SUCCEED trial 59 HspE7 59 oral rivaroxaban 59 goserelin 59 TELINTRA 59 bortezomib Velcade 59 EndoTAGTM 1 59 Genasense ® 59 anti leukemic 59 luteinizing hormone releasing 59 PDE4 inhibitor 59 dalbavancin 59 safety tolerability pharmacokinetic 59 Phase 2b study 59 RG# [001] 59 trastuzumab emtansine T DM1 59 Dasatinib 59 Increlex ® 59 PLK1 SNALP 59 Intravenous CP 59 Laquinimod 59 Trofex 59 Lu AA# 59 Velcade bortezomib 59 ABRAXANE ® 59 vidofludimus 59 Voreloxin 59 M6G 59 APF# 59 Phase 2b clinical trials 59 MEK inhibitor 59 TLK# 59 CD3 monoclonal antibody 59 ospemifene 59 solithromycin 59 BrachySil TM 59 tesmilifene 59 Viramidine 59 Phase 2b clinical 59 Degarelix 59 CYT# potent vascular disrupting 59 PREOS 59 ProSavin 59 Firazyr 59 PEG Interferon lambda 59 Removab 59 Zybrestat 59 registrational trial 59 angiogenesis inhibitor 59 PI3K inhibitor 59 HGS# 59 TELCYTA 59 palifosfamide 59 velafermin 59 Xinlay 59 chemotherapeutic agent 59 virus HCV protease inhibitor 59 relapsed multiple myeloma 59 Squalamine 59 epothilones 59 Phase 2a clinical 59 PLX# 59 motexafin gadolinium Injection 59 Virulizin ® 59 pegfilgrastim 59 Phase #b/#a clinical 59 Tanespimycin 59 alkylating agent 59 MGd 59 Cloretazine 59 Ostabolin C 59 gastrointestinal stromal tumors GIST 59 regorafenib 59 ATL/TV# 59 silodosin 59 BZL# 59 Phase IIb clinical trials 59 TH# [003] 59 Dacogen injection 59 cancer immunotherapies 59 metastatic hormone refractory 59 microplasmin 59 nanopharmaceutical 59 CTAP# Capsules 59 LY# [003] 59 Mepact 59 pitavastatin 59 Hexvix 59 preclinical 59 metastatic renal cell carcinoma 59 PARP inhibitor 59 drug ISA# 59 intravenously administered 59 ulimorelin 59 Nimotuzumab 59 delafloxacin 59 mTOR inhibitor 59 Marqibo TM 59 Phase #/#a 59 Indaflex TM 59 LCP AtorFen 59 phase IIb III 59 Hsp# Inhibitor 59 anti EGFR antibody 59 PRX# 59 chemotherapeutic drug 59 humanized monoclonal antibody 59 Folotyn 59 bone metastases 59 MEK inhibitor RDEA# 58 Phase #/#a trial 58 Azixa 58 AACR NCI EORTC 58 Blinatumomab 58 Panzem R 58 Aflibercept 58 gemcitabine Gemzar 58 HRPC 58 CANCIDAS 58 TEMODAL 58 Phase Ib clinical trials 58 Dalbavancin 58 bendamustine 58 EndoTAG TM 58 PREOS R 58 temsirolimus 58 DermaVir Patch 58 reslizumab 58 ESBA# 58 metastatic HRPC 58 Cannabinor 58 ceftaroline 58 teduglutide 58 Orazol 58 CLORETAZINE TM VNP#M 58 CD# antibody [001] 58 targeting CD# 58 OvaRex R 58 AZILECT ® 58 factor Xa inhibitor 58 preclinically 58 immatics 58 BEXXAR 58 TRV# [001] 58 voclosporin 58 Ceflatonin 58 relapsing multiple sclerosis 58 favorable pharmacokinetic profile 58 Icatibant 58 Advexin 58 Temsirolimus 58 ACAPODENE 58 GLYX 58 Azedra TM 58 anticoagulant reversing agent 58 CD# monoclonal antibody 58 Avastin bevacizumab 58 PROVENGE sipuleucel T 58 iclaprim 58 AeroLEF TM 58 investigational hepatitis C 58 apaziquone 58 Erbitux cetuximab 58 malignant ascites 58 HuMax CD# 58 Elacytarabine 58 trabedersen 58 Phase Ia 58 ISTODAX 58 investigational monoclonal antibody 58 cetuximab Erbitux ® 58 zalutumumab 58 MLN# 58 ZOLINZA 58 randomized Phase III 58 REMUNE R 58 Abraxane 58 Guanilib 58 noninfectious uveitis 58 RE COVER 58 Androxal TM 58 trastuzumab Herceptin 58 tolvaptan 58 rNAPc2 58 Ridaforolimus 58 Locteron 58 CCR9 antagonist 58 R#/MEM # 58 Diamyd ® 58 SIR Spheres 58 diabetic neuropathic pain 58 synthetic peptide 58 Adlea 58 Daclizumab 58 standard chemotherapy regimen 58 antitumor effects 58 rALLy clinical trial 58 KRN# 58 ENMD 58 Taxotere docetaxel 58 Glufosfamide 58 Iluvien ® 58 MNTX 58 Helsinn Healthcare 58 Safinamide 58 HSP# inhibitor 58 atacicept 58 oral anticancer 58 pharmacodynamic properties 58 Vidofludimus 58 anticancer agents 58 ADVANCE PD 58 SERMs 58 ongoing Phase 1b 58 Mitoxantrone 58 Serdaxin 58 PS# [001] 58 PKC# 58 sapacitabine 58 EFAPROXYN 58 HCV NS5B polymerase 58 Methylnaltrexone 58 recurrent GBM 58 Oral NKTR 58 favorable tolerability 58 haematological cancers 58 vandetanib 58 Targretin 58 BiTE 58 INCB# [003] 58 AA amyloidosis 58 pegylated interferons 58 Fx #A 58 ARRY 58 crofelemer 58 LBH# 58 vosaroxin 58 pharmacokinetic PK 58 Atrasentan 58 multicenter Phase II 58 Elagolix 58 Phase 2b 58 RSD# oral 58 PSN# [002] 58 histone deacetylase inhibitor 58 PrevOnco ™ 58 immunotherapeutic agent 58 drug conjugate 58 candidate deforolimus 58 tumor vascular disrupting 58 Microplasmin 58 Phase 2b trial 58 HepaSphere 58 HDAC inhibitor 58 Zysolin TM 58 Herceptin trastuzumab 58 anticancer activity 58 sorafenib 58 IMC A# 58 Insegia 58 Erlotinib 58 Phase IIb clinical 58 Tarmogen 58 eculizumab 58 Trastuzumab 58 metastatic castration resistant 58 taxane 58 tyrosine kinase inhibitor 58 YONDELIS R 58 VAPRISOL 58 antibody MAb 58 placebo controlled Phase 58 Prochymal 58 Neulasta ® 58 drug GAP #B# 58 Desmoteplase 58 cathepsin K inhibitor 58 fluoropyrimidine 58 immunomodulatory 58 Loramyc ® 58 MabCampath 58 CTCE 58 LE DT 58 TYSABRI natalizumab 58 cobiprostone 58 Ambrisentan 58 Phenoptin 58 iniparib 58 orBec 58 AEGR 58 Elesclomol 58 MEPACT 58 NKTR 58 FOLOTYN 58 oral FTY# 58 BAL# [001] 58 hormone refractory prostate cancer 58 receptor tyrosine kinase inhibitor 58 DDP# 58 Clolar ® 58 Valdoxan 58 Phase III trials 58 bioabsorbable stent 58 trastuzumab DM1 58 Factor VIIa 58 MGCD# [002] 58 Kahalalide F 58 randomized controlled Phase 58 Zenvia ™ 58 selective orally bioavailable 58 ALN VSP 58 recurrent ovarian cancer 58 PNP inhibitor 58 DOS# 57 cetuximab Erbitux 57 ADAGIO study 57 custirsen 57 ENMD # 57 Restanza 57 LEP ETU 57 granisetron 57 Pimavanserin 57 GFT# 57 LCP Tacro 57 assessing T DM1 57 Ferumoxytol 57 RGB # 57 phase 2a 57 veltuzumab 57 MYDICAR ® 57 VitiGam 57 Toraymyxin TM 57 SARMs 57 diarrhea predominant irritable 57 docetaxel 57 Triolex 57 erlotinib Tarceva ® 57 oral formulation 57 VivaGel TM 57 evaluating tivozanib 57 camptothecin 57 vemurafenib 57 Rezular 57 Crofelemer 57 metastatic RCC 57 Solazed TM 57 lintuzumab 57 PLX cells 57 Lubiprostone 57 daclizumab 57 OZURDEX ® 57 TLR9 agonist 57 Liprostin 57 Stapled Peptide 57 oral anticoagulant 57 pazopanib 57 vinorelbine 57 abiraterone 57 Taxol paclitaxel 57 Fulvestrant 57 laquinimod 57 omega interferon 57 Omacetaxine 57 iSONEP 57 Crizotinib 57 BMS# 57 cetrorelix 57 TBC# 57 XYOTAX TM 57 ALN TTR# 57 castration resistant prostate cancer 57 TOCOSOL Paclitaxel 57 AZX# 57 Interferon alpha 57 refractory multiple myeloma 57 Acute Radiation Syndrome ARS 57 invasive candidiasis 57 Polymer Microspheres 57 Teysuno 57 rhC1INH 57 LEUKINE 57 lomitapide 57 tolevamer 57 pharmacodynamic effects 57 pharmacokinetic PK study 57 Anticalins 57 CB2 selective receptor agonist 57 BRAF V# mutation 57 HDAC Inhibitor 57 ALGRX 57 dose escalation trial 57 antiangiogenic agents 57 ridaforolimus 57 cannabinor 57 Azilect ® 57 Virulizin R 57 masitinib 57 Aptocine 57 systemically administered 57 Aplidin R 57 trastuzumab DM1 T DM1 57 ImmunoVEX HSV2 57 NEBIDO 57 MDV# 57 antitumor activity 57 Octreotide 57 Vandetanib 57 Bendavia 57 humanized anti 57 Valortim 57 Aliskiren 57 docetaxel Taxotere 57 ANG# 57 Dabigatran etexilate 57 multi kinase inhibitor 57 Darusentan 57 SPC# [001] 57 PDX pralatrexate 57 allosteric modulator 57 mitomycin 57 Zingo TM 57 palonosetron 57 TREANDA 57 mGluR5 NAM 57 Tarceva erlotinib 57 Arikace 57 Phase 1b clinical trials 57 investigational pan BCR 57 CCR5 antagonist 57 molecularly targeted 57 GAP #B# 57 taxane chemotherapy 57 dabigatran etexilate 57 PI3K/Akt pathway inhibitor 57 Epratuzumab 57 nab paclitaxel 57 #I TM# 57 gemcitabine cisplatin 57 oral taxane 57 Vascugel 57 GED aPC 57 cutaneous T cell 57 MT# MEDI 57 immunomodulator 57 pradefovir 57 Canvaxin 57 Cardio Vascu Grow 57 metastatic CRC 57 ANAVEX #-# [003] 57 Defibrotide 57 C1 INH 57 relapsed MM 57 Mycamine 57 GLP toxicology studies 57 Plenaxis TM 57 Phase IIa trial 57 leading oral taxane 57 PEGylated 57 TroVax 57 recurrent NSCLC 57 CRMD# 57 oncology indications 57 chemotherapy induced neutropenia 57 Trabectedin 57 Cerashield 57 radezolid 57 Rivaroxaban 57 dacetuzumab 57 samalizumab 57 ponatinib 57 degarelix 57 ThGRF 57 dose cohorts 57 recurrent glioma 57 Gemcitabine 57 Aganocide 57 novel oral anticoagulant 57 MT#/MEDI-# 57 Dacogen decitabine 57 IND submission 57 Ceflatonin R 57 Bendamustine 57 rALLy trial 57 Menadione 57 LymphoStat B 57 anti angiogenic agent 57 oritavancin 57 Ventavis 57 tolerability 57 CRD5 57 MYDICAR 57 Sorafenib 57 Cotara ® 57 prophylactic vaccine 57 Romidepsin 57 rFIXFc 57 thalidomide Thalomid 57 prostate cancer CRPC 57 Genasense ® oblimersen 57 Olmesartan 57 small molecule Hedgehog 57 ApoB SNALP 57 Lorianne Masuoka MD 57 Halaven 57 otelixizumab 57 roflumilast 57 Natalizumab 57 MVA BN 57 synthetic retinoid 57 highly immunogenic 57 targeted antifolate 57 CG# [003] 57 Juvista 57 Linaclotide 57 Amigal 57 Hyphanox 57 Civacir 57 acyclovir Lauriad ® 57 Imprime PGG 57 albinterferon alfa 2b 57 SUTENT ® 57 tipranavir 57 refractory gout 57 volociximab 57 Junovan 57 cleavable linker 57 melphalan prednisone 57 ZD# [001] 57 Xeloda ® 57 seliciclib CYC# 57 Fleximer 57 VELCADE 57 polymerase inhibitor 57 TNFerade 57 inecalcitol 57 TRISENOX ® 57 MEK Inhibitor 57 Acapodene 57 aflibercept VEGF Trap 57 refractory AML 57 resistant ovarian cancer 57 dose escalation Phase 57 ibandronate 57 Bronchitol 57 refractory CLL 57 tremelimumab 57 Sphingomab 56 IMiDs 56 refractory indolent non 56 Troxatyl 56 lumiliximab 56 PROCHYMAL 56 CINOD 56 Clevudine 56 Nexavar sorafenib 56 GSK# [001] 56 Palonosetron 56 oral mucositis 56 Abbokinase 56 brivaracetam 56 Personalized Immunotherapy 56 LHRH antagonists 56 CORT # 56 olaparib 56 metastatic sarcomas 56 ABSORB trial 56 MIS# 56 paclitaxel Taxol R 56 ZACTIMA 56 EVIZON 56 retaspimycin 56 antitumor effect 56 IV Busulfex 56 FTY# 56 nab docetaxel 56 Trofex TM 56 Capesaris 56 Talabostat 56 paclitaxel Taxol 56 liprotamase 56 UPLYSO 56 valopicitabine 56 analgesic efficacy 56 Xcytrin 56 prostone 56 Akt inhibitor 56 opioid induced bowel dysfunction 56 docetaxel chemotherapy 56 Phase IIb 56 arzoxifene 56 GRN#L 56 FTY# fingolimod 56 iobenguane 56 LEVADEX 56 inhaled formulation 56 pegylated liposomal doxorubicin 56 TMC# [002] 56 CINTREDEKIN BESUDOTOX 56 Randomized Phase 56 ARIKACE 56 chimeric monoclonal antibody 56 Hepatocellular Carcinoma HCC 56 AzaSite Plus 56 Curaxin 56 glioblastoma multiforme GBM 56 Cytoxan 56 lintuzumab SGN 56 Oxaliplatin 56 Catena ® 56 odanacatib 56 seliciclib 56 Aviptadil 56 IAP inhibitor 56 Asentar 56 MKC# MKC# PP 56 dose cohort 56 Genz # 56 vismodegib 56 lenalidomide Revlimid R 56 ZEVALIN ® 56 Relivar 56 CIMZIA ™ 56 recurrent metastatic 56 GAMMAGARD 56 Maribavir 56 ZADAXIN ® 56 intradermal injection 56 indolent NHL 56 Urocidin TM 56 Doxorubicin

Back to home page